A German retrospective cohort study by Sarabhai et al., which included 38140 adult patients with T2DM, found that SGLT2 inhibitor use was associated with a 20% relative risk reduction for dementia compared to DPP-4 inhibitors (hazard ratio (HR): 0.80; 95% confidence interval (CI): 0.70-0.93) [4]. This protective effect was noted to be even more pronounced in male patients and in the very elderly (age >80 years) with HR: 0.77 and HR: 0.75, respectively [4]. Here, SLC5A2 is linked to dementia.